DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Pirarubicin is an investigational drug.
There have been 22 clinical trials for Pirarubicin. The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2012.
The most common disease conditions in clinical trials are Carcinoma, Carcinoma, Transitional Cell, and Breast Neoplasms. The leading clinical trial sponsors are Sun Yat-sen University, Peking Union Medical College Hospital, and Peking University First Hospital.
There is one US patent protecting this investigational drug and twenty-six international patents.
Recent Clinical Trials for Pirarubicin
|Gemcitabine Versus Water Irrigation in Upper Tract Urothelial Carcinoma||University of Texas Southwestern Medical Center||Phase 3|
|Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy||Chinese Academy of Medical Sciences||Phase 2|
|Combination Therapy of Anthracyclines for Children With Nephroblastoma||Shengjing Hospital||Phase 4|
Top disease conditions for Pirarubicin
Top clinical trial sponsors for Pirarubicin
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Pirarubicin||⤷ Free Forever Trial||Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus||Seattle Genetics, Inc. (Bothell, WA)||⤷ Free Forever Trial|
|Pirarubicin||⤷ Free Forever Trial||Methods for sensitizing a quiescent cancer stem cell to a BCR-ABL inhibitor||The Regents of the University of California (Oakland, CA)||⤷ Free Forever Trial|
|Pirarubicin||⤷ Free Forever Trial||Use of inhibitors of Bruton's tyrosine kinase (Btk)||Pharmacyclics LLC (Sunnyvale, CA)||⤷ Free Forever Trial|
|Pirarubicin||⤷ Free Forever Trial||Substituted indole Mcl-1 inhibitors||Vanderbilt University (Nashville, TN)||⤷ Free Forever Trial|
|Pirarubicin||⤷ Free Forever Trial||Pyrrolidinone derivatives as MetAP-2 inhibitors||Merck Patent GmbH (Darmstadt, DE)||⤷ Free Forever Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Pirarubicin||Australia||AU2006269422||2025-07-07||⤷ Free Forever Trial|
|Pirarubicin||Canada||CA2614436||2025-07-07||⤷ Free Forever Trial|
|Pirarubicin||European Patent Office||EP1917020||2025-07-07||⤷ Free Forever Trial|
|Pirarubicin||European Patent Office||EP2722051||2025-07-07||⤷ Free Forever Trial|
|Pirarubicin||European Patent Office||EP3498289||2025-07-07||⤷ Free Forever Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|